Half Year 2025 Roche Holding AG Earnings Call Transcript
Key Points
- Roche Holding AG (RHHBF) reported a strong group sales increase of 7%, with pharmaceuticals growing by 10%.
- Core operating profit grew by 11%, with core EPS increasing by 12%, indicating strong bottom-line performance.
- The company achieved significant regulatory milestones, including EU approval of Itovebi and US approval of Susvimo.
- Roche is actively refilling its pipeline with new medicines, moving four into Phase III this year, with more expected.
- The Diagnostics division is preparing for the launch of the AXELIOS sequencing solution in 2026, which promises to be disruptive in terms of speed and accuracy.
- Diagnostics sales were flat due to the China Healthcare pricing reforms, impacting overall growth.
- The company faced mixed results with astegolimab, with one positive and one negative study outcome.
- There is ongoing geopolitical uncertainty, which could impact future guidance and operations.
- The US FDA issued a Complete Response Letter (CRL) for Columvi in second-line DLBCL, affecting its market potential.
- The company is facing challenges with biosimilar erosion, particularly with Actemra in Europe, which is expected to accelerate.
On your phone's dial pad. When you then get selected to ask your questions, please follow the instructions from the phone and press 6 to unmute yourself. One last remark. If you'd like to follow the presented slides on your end as well, please feel free to go to roche.com/investors to download the presentation. At this time, it's my pleasure to introduce you to Thomas Schinecker, CEO of Group; Mr. Schinecker, the stage is yours.
Thank you very much, and good morning, good afternoon or good evening wherever you are. I'm really happy to talk to you about our half year results, which have been extremely strong.
So let me kick it off on this slide. So overall, our group sales increased by 7%. So a very strong growth by pharma with 10%. In fact, if you look at the momentum in Q2, pharma even grew by 11%. Diagnostics was flat, so very similar to what we saw in the first quarter and this is purely due to the China Healthcare pricing reforms.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
